Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL | Q9Y232 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | IAPP | P10997 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7340131 | 0.87 | TDP1 (0.58) | CDYLKDM4EMTNR1ACYP1A2CYP2C19 | |
| SCHEMBL13227200 | 0.86 | TDP1 (0.56) | CDYLCYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL6282199 | 0.81 | MTNR1A (0.50) | CDYLKDM4EMTNR1ACYP1A2TDP1 | |
| SCHEMBL8400463 | 0.81 | IAPP (0.58) | CDYLKDM4EMTNR1ACYP1A2CYP2D6 | |
| SCHEMBL9404001 | 0.80 | MTNR1A (0.58) | CDYLKDM4EMTNR1ACYP1A2TDP1 | |
| SCHEMBL605212 | 0.80 | HTR2A (0.61) | CYP1A2CYP2D6CYP2C19HTR2A | |
| SCHEMBL6708222 | 0.80 | MTNR1A (0.50) | CDYLKDM4EMTNR1ACYP1A2TDP1 | |
| SCHEMBL6422150 | 0.80 | CDYL (0.53) | CDYLKDM4EMTNR1ACYP1A2CYP2D6 | |
| SCHEMBL11983099 | 0.79 | CDYL (0.64) | CDYLKDM4EMTNR1ATDP1GPR84 | |
| SCHEMBL27891939 | 0.78 | TDP1 (0.51) | CDYLKDM4EMTNR1ACYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030017-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ANDRIES KOENRAAD JOZEF LODEWIJK MARCEL (BE) | 2013-01-31 | — | — | US | disclosed |
| US-20130030017-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ANDRIES KOENRAAD JOZEF LODEWIJK MARCEL (BE) | 2013-01-31 | — | — | US | disclosed |
| US-20100204270-A1 | Quinoline Derivatives as Antibacterial Agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204270-A1 | Quinoline Derivatives as Antibacterial Agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-12 | — | — | US | disclosed |
| WO-2007000436-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204270-A1 | Quinoline Derivatives as Antibacterial Agents | NQO2, NDUFB7, NQO1 | CDYL 4291/4885KDM4E 4433/4885MTNR1A 1183/4885 |
| US-20130030017-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | NQO2, NDUFB7, NDUFA7 | CDYL 4560/4885KDM4E 4224/4885MTNR1A 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.